ReviewJournal of the American Academy of Dermatology2011
Update on morphea: part II. Outcome measures and treatment.
Review in Journal of the American Academy of Dermatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 163 citations in OpenAlex.
- Interventions for morphea.The Cochrane database of systematic reviews · 2019Pooled it
- Development of minimum standards of care for juvenile localized scleroderma.European journal of pediatrics · 2018Pooled it
- Pirfenidone gel in patients with localized scleroderma: a phase II study.Arthritis research & therapy · 2015Trial
- High-frequency ultrasound evaluation of morphea: Retrospective analytical study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- [Localized scleroderma].Dermatologie (Heidelberg, Germany) · 2024Review
- Recent Advances in Treatment of Systemic Sclerosis and Morphea.American journal of clinical dermatology · 2024Review
- A Comparison of Clinical, Demographic and Treatment Characteristics of Pediatric-Onset and Adult-Onset Patients Diagnosed With Localized Scleroderma.Dermatology practical & conceptual · 2024Article
- Article
- Unravelling morphoea aetiopathogenesis by next-generation sequencing of paired skin biopsies.Archives of dermatological research · 2023Article
- Clinical and therapeutic course in head variants of linear morphea in adults: a retrospective review.Archives of dermatological research · 2023Article
- Role of imaging in morphea assessment: A review of the literature.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2023Review
- Morphea: The 2023 update.Frontiers in medicine · 2023Review
- Concentrations of metalloproteinase-1 in patients with morphea treated with phototherapy: a preliminary study.Postepy dermatologii i alergologii · 2022Article
- Skin sonography in children: a review.Pediatric radiology · 2022Review
- Effectiveness of PUVA vs. UVA1 phototherapy in the treatment of morphea patients.Postepy dermatologii i alergologii · 2022Article
- Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection.Clinical case reports · 2022Article
- Upcoming treatments for morphea.Immunity, inflammation and disease · 2021Review
- Skin Manifestations after Ionizing Radiation Exposure: A Systematic Review.Bioengineering (Basel, Switzerland) · 2021Review
- Clinical Approach to Linear Hyperpigmentation: A Review Article.Clinical, cosmetic and investigational dermatology · 2021Review
- Histopathological Coexistence of Extragenital Lichen Sclerosus and Morphea in a Single Lesion.Cureus · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.